Ads
related to: treatment for carcinoid syndrome
Search results
Results From The WOW.Com Content Network
Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary to neuroendocrine tumors (formerly known as carcinoid tumors). [1] The syndrome is caused by neuroendocrine tumors most often found in the gut releasing biologically active substances into the blood causing symptoms such as flushing and diarrhea, and less frequently, heart failure, vomiting ...
A carcinoid (also carcinoid tumor) is a slow-growing [1] type of neuroendocrine tumor originating in the cells of the neuroendocrine system. In some cases, metastasis may occur. Carcinoid tumors of the midgut (jejunum, ileum, appendix, and cecum) are associated with carcinoid syndrome. Sometimes, carcinoids cause paraneoplastic syndromes, which ...
This can occur as a result of alcoholism, long-term diarrhea, carcinoid syndrome, Hartnup disease, and a number of medications such as isoniazid. [1] Diagnosis is typically based on symptoms and may be assisted by urine testing. [3] Treatment is with either niacin or nicotinamide supplementation. [1]
Treatments have improved over the past several decades, and outcomes are improving. [49] In malignant carcinoid tumors with carcinoid syndrome, the median survival has improved from two years to more than eight years. [75] Detailed guidelines for managing neuroendocrine tumors are available from ESMO, [76] NCCN [77] and a UK panel. [1]
Lanreotide. Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Lanreotide (as lanreotide acetate) is manufactured by Ipsen.
A small intestine neuroendocrine tumor is a carcinoid in the distal small intestine or the proximal large intestine. It is a relatively rare cancer and is diagnosed in approximately 1/100000 people every year. In recent decades the incidence has increased. [1] The prognosis is comparatively good with a median survival of more than 8 years. [2]
It is indicated for symptomatic treatment of carcinoid syndrome and acromegaly. [ 22 ] [ 23 ] It is also finding increased use in polycystic diseases of the liver and kidney. Lanreotide (Somatuline, Ipsen Pharmaceuticals ) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid ...
Hepatic artery embolization, also known as trans-arterial embolization (TAE), is one of the several therapeutic methods to treat primary liver tumors or metastases to the liver. The embolization therapy can reduce the size of the tumor, and decrease the tumor's impact such its hormone production, effectively decreasing symptoms.